Molecular characterization and monitoring of patient ctDNA in phase I study of H3B-6545 in ER+ MBC.

1052Background: Because of lack of effective treatment in endocrine resistant metastatic breast cancer (MBC), we developed H3B-6545, a novel selective ERa covalent antagonist, capable of irreversib...